B. Andemariam

Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration.

The emerging role of repurposed low-cost therapies, particularly hydroxyurea and thalidomide, as disease-modifying options in resource-limited settings are discussed and opportunities to democratise access to curative gene therapies through technological developments, decentralised manufacturing, regional collaboration...